Intriguingly, recent genetic studies further linked many loss-of-function CACNA1A variants to neurodevelopmental disorders such as developmental delay and developmental epileptic encephalopathy [23, 26, 29, 41, 43], highlighting the clinical significance of developing new treatment aiming at correcting defective CaV2.1 proteostasis resulting from the dominant-negative effect of loss-of-function CACNA1A variants [41]. This evidence concerns the gene CACNA1A and Global developmental delay.